abstract |
The known peroxisome proliferator activated receptor gamma (PPAR. q. ) agonists rosiglitazone, pioglitazone, troglitazone and KRP-297 have been found to inhibit Interleukin-10 (IL-10) production. Such compounds find use in the prevention or treatment the following diseases - systemic lupus erythematosus, infectious diseases, AIDS (especially related lymphomas), cancer, transplantation, burn-injury-induced immune suppression, psoriasis, rheumatoid arthritis, diseases where high Th1 responses are therapeutic and allergic diseases. |